Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Molecular properties of fatty acids related to PPAR binding and metabolic diseases (2013)

  • Authors:
  • USP affiliated authors: HONORIO, KÁTHIA MARIA - EACH
  • USP Schools: EACH
  • DOI: 10.1007/s00044-012-0285-6
  • Subjects: MODELAGEM MOLECULAR; PLANEJAMENTO DE FÁRMACOS; ÁCIDOS GRAXOS
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s00044-012-0285-6 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Versões disponíveis em Acesso Aberto do: 10.1007/s00044-012-0285-6 (Fonte: Unpaywall API)

    Título do periódico: Medicinal Chemistry Research

    ISSN: 1054-2523,1554-8120



      Não possui versão em Acesso aberto
    Informações sobre o Citescore
  • Título: Medicinal Chemistry Research

    ISSN: 1054-2523

    Citescore - 2017: 1.61

    SJR - 2017: 0.422

    SNIP - 2017: 0.765


  • How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      MALTAROLLO, Vinícius Gonçalves; HONÓRIO, Kathia Maria. Molecular properties of fatty acids related to PPAR binding and metabolic diseases. Medicinal Chemistry Research, Basel, v. 22, n. 7, p. 3126\20133133, 2013. Disponível em: < http://dx.doi.org/10.1007/s00044-012-0285-6 > DOI: 10.1007/s00044-012-0285-6.
    • APA

      Maltarollo, V. G., & Honório, K. M. (2013). Molecular properties of fatty acids related to PPAR binding and metabolic diseases. Medicinal Chemistry Research, 22( 7), 3126\20133133. doi:10.1007/s00044-012-0285-6
    • NLM

      Maltarollo VG, Honório KM. Molecular properties of fatty acids related to PPAR binding and metabolic diseases [Internet]. Medicinal Chemistry Research. 2013 ; 22( 7): 3126\20133133.Available from: http://dx.doi.org/10.1007/s00044-012-0285-6
    • Vancouver

      Maltarollo VG, Honório KM. Molecular properties of fatty acids related to PPAR binding and metabolic diseases [Internet]. Medicinal Chemistry Research. 2013 ; 22( 7): 3126\20133133.Available from: http://dx.doi.org/10.1007/s00044-012-0285-6

    Referências citadas na obra
    Berger J, Moller DE (2002) The mechanisms of actions of PPARs. Annu Rev Med 53:409–435
    Billin AN (2008) PPAR-beta/delta agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin Investig Drugs 17:1465–1471
    Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA (2006) Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. ATVB 26:28–40
    Connors RV, Wang Z, Harrison M, Zhang A, Wanska M, Hiscock S, Fox B, Dore M, Labelle M, Sudom A, Johnstone S, Liu J, Walker NPC, Chai A, Siegler K, Li Y, Coward P (2009) Identification of a PPAR[delta] agonist with partial agonistic activity on PPAR[gamma]. Bioorg Med Chem Lett 19:3550–3554
    Da Silva SL, da Silva A, Honório KM, Marangoni S, Toyama MH, Da Silva ABF (2004) The influence of electronic, steric and hydrophobic properties of flavonoid compounds in the inhibition of the xanthine oxidase. J Mol Struct (Theochem) 684:1–7
    Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JA Jr, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Iyengar SS, Tomasi J, Cossi M, Rega N, Millam NJ, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas Ö, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ (2009) Gaussian 09. Gaussian, Inc., Wallingford
    Garcia TS, Honório KM (2011) Two-dimensional quantitative structure-activity relationship studies on bioactive ligands of peroxisome proliferator-activated receptor D. J Braz Chem Soc 22:65
    Gomes MDB (2006) Glitazonas e síndrome metabólica: mecanismos de ação, fisiopatologia e indicações terapêuticas. Arq Bras Endocrinol Metabol 50:271–280
    Gross B, Staels B (2007) PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 21:687–710
    Havranek M, Sauerberg P, Mogensen JP, Kratina P, Jeppesen CB, Pettersson I, Pihera P (2007) Novel selective PPAR[delta] agonists: optimization of activity by modification of alkynylallylic moiety. Bioorg Med Chem Lett 17:4144–4149
    Honório KM, Da Silva ABF (2003) An AM1 study on the electron-donating and electron-accepting character of biomolecules. Int J Quantum Chem 95:126–132
    Honório KM, Da Silva ABF (2005) A study on the influence of molecular properties in the psychoactivity of cannabinoid compounds. J Mol Model 11:200–209
    James JPS (1989a) Optimization of parameters for semiempirical methods I. Method. J Comput Chem 10:209–220
    James JPS (1989b) Optimization of parameters for semiempirical methods II. Applications. J Comput Chem 10:221–264
    Li Y, Choi M, Suino K, Kovach A, Daugherty J, Kliewer SA, Xu HE (2005) Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner. Proc Natl Acad Sci USA 102:9505–9510
    Malta VRS, Pinto AV, Molfetta FA, Honório KM, de Simone CA, Pereira MA, Santos RHA, Da Silva ABF (2003) The influence of electronic and steric effects in the structure–activity relationship (SAR) study of quinone compounds with biological activity against Trypanosoma cruzi. J Mol Struct (Theochem) 634:271–280
    Maltarollo VG, Homem-de-Mello P, Honório KM (2010) Theoretical study on the molecular and electronic properties of some substances used for diabetes mellitus treatment. J Mol Model 16:799–804
    Maltarollo VG, Homem-de-Mello P, Honório KM (2011) Role of physicochemical properties in the activation of peroxisome proliferator-activated receptor δ. J Mol Model 17:2549–2558
    Miller AR (2006) Today’s challenges and tomorrow’s opportunities: ligands to peroxisome proliferator-activated receptors as therapies for type 2 diabetes and the metabolic syndrome. Drug Dev Res 67:574–578
    Parra S, Rivera LCM (2001) Implicaciones farmacológicas de los receptores activados por los proliferadores de peroxisomas (PPAR). IATREIA 14:35–46
    Robinson E, Grieve DJ (2009) Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther 122:246–263
    Rudolph J, Chen L, Majumdar D, Bullock WH, Burns M, Claus T, Dela Cruz FE, Daly M, Ehrgott FJ, Johnson JS, Livingston JN, Schoenleber RW, Shapiro J, Yang L, Tsutsumi M, Ma X (2007) Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPARa/g/d pan agonists: synthesis, structure–activity relationship, and in vivo efficacy. J Med Chem 50:984–1000
    Sierra ML, Beneton VR, Boullay A-BND, Boyer T, Brewster AG, Donche FDR, Forest M-C, Fouchet M-HIN, Gellibert FOJ, Grillot DA, Lambert MH, Laroze A, Le Grumelec C, Linget JM, Montana VG, Nguyen V-L, Nicodème E, Patel V, Penfornis A, Pineau O, Pohin D, Potvain F, Poulain GR, Ruault CCB, Saunders M, Toum JRM, Xu HE, Xu RX, Pianetti PM (2007) Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARα agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem 50:685–695
    The PyMOL Molecular Graphics System, v0.99 (2006) DeLano Scientific LLC, South San Francisco, California
    Wickens P, Zhang C, Ma X, Zhao Q, Amatruda J, Bullock W, Burns M, Cantin L-D, Chuang C-Y, Claus T, Dai M, Dela Cruz F, Dickson D, Ehrgott FJ, Fan D, Heald S, Hentemann M, Iwuagwu CI, Johnson JS, Kumarasinghe E, Ladner D, Lavoie R, Liang S, Livingston JN, Lowe D, Magnuson S, Mannelly G, Mugge I, Ogutu H, Pleasic-Williams S, Schoenleber RW, Shapiro J, Shelekhin T, Sweet L, Town C, Tsutsumi M (2007) Indanylacetic acids as PPAR-[delta] activator insulin sensitizers. Bioorg Med Chem Lett 17:4369–4373
    Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV (1999) Molecular recognition of fatty acids by peroxisome proliferator–activated receptors. Mol Cell 3:397–403